Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Input metadata referenced "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 20-F Annual Report
Reporting Period: Fiscal Year ended December 31, 2006 (Fiscal 2006). This represents the second full year since the company changed its fiscal year-end from June 30 to December 31.
Business Overview: Adherex is a development-stage biopharmaceutical company focused on cancer therapeutics. It has no commercial product sales and generates no revenue. Its primary activities involve the research and development (R&D) of product candidates, including ADH-1 (an anti-cancer drug targeting N-cadherin), eniluracil (a DPD inhibitor to enhance 5-FU chemotherapy), and STS (a chemoprotectant against hearing loss).
Key Financial Metrics (Fiscal 2006)
| Metric | Value (U.S. Dollars) |
|---|---|
| Revenue | $0 (No product sales) |
| Net Loss (Canadian GAAP) | $(19.1) million |
| Net Loss (U.S. GAAP) | $(16.4) million |
| Net Loss Per Share (Basic & Diluted) | $(0.40) (Canadian GAAP) / $(0.34) (U.S. GAAP) |
| Research & Development Expenses | $14.0 million |
| General & Administrative Expenses | $2.9 million |
| Cash and Cash Equivalents (Dec 31, 2006) | $5.7 million |
| Working Capital | $1.2 million |
| Shareholders' Equity (Canadian GAAP) | $7.6 million |
| Shareholders' Equity (U.S. GAAP) | $1.3 million |
| Accumulated Deficit | $(71.5) million |
Material Changes vs. Prior Period
- Net Loss: The net loss decreased slightly from $19.2 million in Fiscal 2005 to $19.1 million in Fiscal 2006 (Canadian GAAP). This was driven by a lower impairment charge in 2006 ($2.0 million for NAC) compared to 2005 ($3.5 million for mesna), partially offset by increased R&D expenses.
- R&D Expenses: Increased by approximately 13% to $14.0 million, primarily due to the advancement of ADH-1 into Phase II clinical trials and the full-year development of eniluracil (licensed from GSK in July 2005).
- Impairment Charges: In Q4 2006, the company recorded a $2.0 million impairment of intellectual property related to N-acetylcysteine (NAC) as it ceased development plans for this candidate to focus resources on ADH-1 and eniluracil.
- Liquidity: Cash and cash equivalents declined from $13.1 million in 2005 to $5.7 million in 2006, reflecting a cash burn rate of approximately $1.1 million per month.
Guidance, Outlook, and Risks
- Capital Requirements: Management believes current cash resources are sufficient to fund operations into the fourth quarter of 2008. However, the company will need to raise substantial additional funds thereafter to continue clinical trials and operations.
- Recent Financing: On February 21, 2007 (subsequent to the reporting period), the company completed a public offering raising $25.0 million in gross proceeds ($23.3 million net).
- Strategic Developments:
- Eniluracil: On March 1, 2007, the company purchased all remaining buy-back options from GlaxoSmithKline (GSK) for $1.0 million, regaining full control of the asset.
- ADH-1: GSK's option to license ADH-1 expired unexercised in October 2006, allowing Adherex to pursue independent development or partnerships.
- Clinical Progress: Patient enrollment for single-agent ADH-1 Phase Ib/II and Phase II studies was completed by December 31, 2006. Combination trials with chemotherapy agents were initiated in late 2006.
- Key Risks:
- Development Risk: Product candidates are in early clinical stages; failure in trials or inability to obtain regulatory approval would be fatal to the business.
- Financial Risk: History of significant losses with no revenue; reliance on equity financing which may dilute shareholders.
- Collaboration Risk: Dependence on third-party collaborators (e.g., SIOPEL, NCI) for clinical trials; termination of these agreements could delay development.
- Intellectual Property: Some candidates (STS, NAC) are protected only by "method of use" patents, offering less protection than "composition of matter" patents.
Investor Verification Checklist
- Cash Runway: Verify the impact of the February 2007 $25 million offering on the projected cash runway into late 2008.
- GAAP Reconciliation: Review the significant difference between Canadian GAAP equity ($7.6M) and U.S. GAAP equity ($1.3M), primarily due to the treatment of acquired intellectual property as an immediate expense (IPRD) under U.S. GAAP.
- Clinical Trial Status: Confirm the status of the randomized STS trial with SIOPEL and the ADH-1 combination trials, as delays could increase burn rates.
- Eniluracil Milestones: Assess the financial obligation of potential future milestone payments to GSK (up to $70 million plus royalties) upon FDA approval.
- Dilution: Evaluate the dilution impact of the large number of outstanding warrants and options (approx. 192 million total securities outstanding as of Feb 2007).